In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors

Journal of Hepatology

Volumn 56, Issue 1, 2012, Pages 41-48

  Delang, Leen ^a   Vliegen, Inge ^a   Leyssen, Pieter ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Combination; Hepatitis C virus; Non nucleoside polymerase inhibitors; Resistance

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE; BENZOTHIADIAZINE DERIVATIVE; GSK 4; JT 16; NESBUVIR; THENOIC ACID; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL PROTOCOL; DRUG EFFECT; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE BINDING SITE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS CHARACTERIZATION; VIRUS REPLICATION;

ALLOSTERIC SITE; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME INHIBITORS; GENES, VIRAL; HEPACIVIRUS; HUMANS; MUTATION; REPLICON; RNA REPLICASE; SELECTION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 83555174694     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.04.016     Document Type: Article

References (17)

1. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-344.
2. C.A. Lesburg, M.B. Cable, E. Ferrari, Z. Hong, A.F. Mannarino, and P.C. Weber Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat Struct Biol 6 1999 937 943 (Pubitemid 29463307)
3. L. Delang, L. Coelmont, and J. Neyts Antiviral therapy For Hepatitis C Virus: beyond the standard of care Viruses 2 2010 826 866
4. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, and M. Welker Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor Telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
5. Stephen Villano, Anita Howe, Donald Raible, Dawn Harper, John Speth, and Geraldine Bichier Analysis of Hcv Ns5b genetic variants following monotherapy with Hcv-796, a nonnucleoside polymerase inhibitor, in treatment-naïve Hcv-infected patients Hepatology 44 2006 607a 608a
6. M.F. Mccown, S. Rajyaguru, S. Le Pogam, S. Ali, W.R. Jiang, and H. Kang The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors Antimicrob Agents Chemother 52 2008 1604 1612 (Pubitemid 351614649)
7. M. Flint, S. Mullen, A.M. Deatly, W. Chen, L.Z. Miller, and R. Ralston Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors Hcv-796 and Boceprevir (Sch 503034) Antimicrob Agents Chemother 53 2009 401 411
8. S. Le Pogam, H. Kang, S.F. Harris, V. Leveque, A.M. Giannetti, and S. Ali Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus J Virol 80 2006 6146 6154 (Pubitemid 43849192)
9. Le Pogam S, Chhabra M, Ali S, Yan J, Ilnicka MJ, Kang H, Wong J, Kosaka A, Ewing A, Seshaadri A, De La Rosa A, Bradford W, Klumpp K, Shulman N, Smith PF, Cammack N, Najera I. Combination therapy with nucleoside polymerase R7128 and protease R7227/Itmn-191 inhibitors in genotype 1 Hcv infected patients: interim resistance analysis of inform-1 cohorts A-D. 60th Annual Meeting Of The American Association For The Study Of Liver Diseases, 2009,1580.
10. L. Delang, J. Paeshuyse, I. Vliegen, P. Leyssen, S. Obeid, and D. Durantel Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development Hepatology 50 2009 6 16
11. J. Paeshuyse, I. Vliegen, L. Coelmont, P. Leyssen, O. Tabarrini, and P. Herdewijn Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors Antimicrob Agents Chemother 52 2008 3433 3437
12. Mark N. Prichard, and Charles Shipman Jr. A three-dimensional model to analyze drug-drug interactions Antiviral Res 14 1990 181 205 (Pubitemid 20377558)
13. A.Y. Howe, H. Cheng, S. Johann, S. Mullen, S.K. Chunduru, and D.C. Young Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, Hcv-796 Antimicrob Agents Chemother 52 2008 3327 3338
14. G. Kukolj, G.A. Mcgibbon, G. Mckercher, M. Marquis, S. Lefebvre, and L. Thauvette Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus Ns5b polymerase J Biol Chem 280 2005 39260 39267 (Pubitemid 41713879)
15. R. Chase, A. Skelton, E. Xia, S. Curry, S. Liu, and P. Mcmonagle Novel Hcv Ns3 protease mutation selected by combination treatment of the protease inhibitor Boceprevir and Ns5b polymerase inhibitors Antiviral Res 84 2009 178 184
16. C.M. Chen, Y. He, L. Lu, H.B. Lim, R.L. Tripathi, and T. Middleton Activity of a potent hepatitis C virus polymerase inhibitor in the Chimpanzee model Antimicrob Agents Chemother 51 2007 4290 4296 (Pubitemid 350209879)
17. C. Lin, C.A. Gates, B.G. Rao, D.L. Brennan, J.R. Fulghum, and Y.P. Luong In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, Vx-950 and Biln 2061 J Biol Chem 280 2005 36784 36791 (Pubitemid 41587758)